OncoSil Medical (ASX:OSL) - Managing Director & CEO, Daniel Kenny
Managing Director & CEO, Daniel Kenny
Sourced: Daniel Kenny
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • OncoSil Medical (OSL) has announced that its namesake medical device has been granted breakthrough device designation by the Food and Drug Administration
  • This designation will accelerate the development and approval of the medical imaging device in the U.S. market
  • The OncoSil medical device is implanted directly into a patient’s pancreatic tumour via ultrasound guidance
  • The ultrasound then uses high-frequency sound waves to produce detailed images of the lining and walls of specific organs
  • Chemotherapy is used in tandem with this device to destroy the cancerous cells
  • OncoSil has skyrocketed 35.9 per cent in mid-morning trade with shares currently trading for 12.5 cents each

OncoSil Medical (OSL) has announced that its OncoSil medical device has been granted breakthrough device designation by the FDA.

This designation is a significant milestone for the company as breakthrough designation will accelerate the development and approval of the device in the U.S. market.

The Breakthrough Devices Program (BDP) is intended to speed up the FDA (Food and Drug Administration) review and approval of designated devices that may provide more effective treatment of life-threatening or irreversibly debilitating diseases.

OncoSil will now work closely with the FDA to ensure that the proposed premarket approval (PMA) evidence development and clinical trials capture meaningful data.

“The granting of Breakthrough Device Designation by FDA of the OncoSil device offers the company many benefits with respect to PMA trial design, device assessment and expedited review,” CEO and Managing Director Daniel Kenny said.

“Breakthrough designation also provides validation of the OncoSil device as it represents a novel technology that has the potential to provide clinically meaningful benefits to patients,” he added.

The OncoSil device is designated for the use of treatment of patients with advanced and unremovable pancreatic cancer. This is used in tandem with standard chemotherapy.

Current treatment options for cancerous cells include surgery, radiation therapy, chemoradiation therapy, or chemotherapy.

While surgery may not be an option depending on the location of the cancer, OncoSil’s device can still be used to identify the cancerous cell’s location.

The OncoSil device is a brachytherapy (treatment of cancer) device that implants a pre-determined dose of beta radiation directly into cancerous tissue.

The beta particles that are emitted by OncoSil travel a short distance in the tissue causing damage to cancer cell DNA.

This locates cancerous cells while chemotherapy is used to destroy them.

OncoSil has skyrocketed 35.9 per cent in mid-morning trade with shares trading for 12.5 cents each at 11:30 am AEDT.

OSL by the numbers
More From The Market Online

Vitura joint venture prescribes shrooms for therapeutic use in Australian-first

In an Australian-first pharmaceutical achievement, Vitura Health Limited has announced the first ever shipment of 'shrooms'…

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Recce Pharmaceuticals (ASX: RCE) has announced the successful dosing of the latest group of human participants…
The Market Online Video

Recce Pharmaceuticals secures AUD$11.18M from Endpoints Capital

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) has announced the receipt of an AUD$11,178,965 R&D Advance from Endpoints Capital.